{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:54:56Z","timestamp":1794030896855,"version":"4.8.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.msard.2026.107921","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:53:06Z","timestamp":1789120386000},"page":"107921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Optimizing rituximab dosing in multiple sclerosis: Real-world outcomes with interval extension"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7521-2728","authenticated-orcid":false,"given":"N","family":"Pulukuri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Alva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2269-5312","authenticated-orcid":false,"given":"L","family":"Pandit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N","family":"Agasti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Vegda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Chinni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Kadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9 Suppl","key":"10.1016\/j.msard.2026.107921_bib0010","first-page":"NP1","article-title":"Relaxing rituximab infusion intervals may be a cost-effective and safe recommendation for management of multiple sclerosis","volume":"30","author":"Alva","year":"2024","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107921_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105009","article-title":"Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: pathogenesis, risk of infection, and disease management","volume":"79","author":"Alvarez","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107921_bib0015","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S1474-4422(25)00304-7","article-title":"2024 MAGNIMS\u2013CMSC\u2013NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosis","volume":"24","author":"Barkhof","year":"2025","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107921_bib0008","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200152","article-title":"Efficacy of rituximab outlasts B-cell repopulation in multiple sclerosis: time to rethink dosing?","volume":"10","author":"Claverie","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2026.107921_bib0007","article-title":"Sustained low relapse rate with highly variable B-cell repopulation dynamics with extended rituximab dosing intervals in multiple sclerosis","volume":"10","author":"Cucuzza","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2026.107921_bib0004","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1002\/acn3.70142","article-title":"Comparative effect of standard versus extended interval dosing of rituximab or ocrelizumab in multiple sclerosis","volume":"12","author":"El Ayoubi","year":"2025","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2026.107921_bib0014","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1474-4422(15)00393-2","article-title":"MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines","volume":"15","author":"Filippi","year":"2016","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107921_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106400","article-title":"Early extended interval dosing of rituximab in multiple sclerosis: a comparative cohort study on efficacy and safety","volume":"97","author":"Fossum","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2026.107921_bib0012","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.msard.2015.04.006","article-title":"Is it time to target no evident disease activity (NEDA) in multiple sclerosis?","volume":"4","author":"Giovannoni","year":"2015","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2026.107921_bib0001","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jamaneurol.2017.4011","article-title":"Comparative effectiveness of rituximab and other initial treatment choices for multiple sclerosis","volume":"75","author":"Granqvist","year":"2018","journal-title":"JAMa Neurol."},{"issue":"9","key":"10.1016\/j.msard.2026.107921_bib0013","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2026.107921_bib0017","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1136\/jnnp-2018-318465","article-title":"Less frequent rituximab retreatment maintains remission of neuromyelitis optica spectrum disorder, following long-term rituximab treatment","volume":"90","author":"Kim","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"2","key":"10.1016\/j.msard.2026.107921_bib0016","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3988\/jcn.2024.0485","article-title":"Evaluating rituximab failure rates in neuromyelitis optica spectrum disorder: a nationwide real-world study from South Korea","volume":"21","author":"Kim","year":"2025","journal-title":"J. Clin. Neurol."},{"key":"10.1016\/j.msard.2026.107921_bib0020","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200211","article-title":"Multiple sclerosis, rituximab, hypogammaglobulinemia, and risk of infections","volume":"11","author":"Langer-Gould","year":"2024","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2026.107921_bib0018","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000214917","article-title":"Comparative effectiveness of rituximab dosed every 6 and 12 months in relapsing multiple sclerosis","volume":"106","author":"Langer-Gould","year":"2026","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107921_bib0021","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/13524585261430130","article-title":"De-escalating low-dose rituximab up to every 24-month infusions and the risk of disease activity in multiple sclerosis","volume":"32","author":"Langer-Gould","year":"2026","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2026.107921_bib0009","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000825","article-title":"Extending rituximab dosing intervals in patients with multiple sclerosis during the COVID-19 pandemic and beyond","volume":"7","author":"Maarouf","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.msard.2026.107921_bib0011","doi-asserted-by":"crossref","first-page":"740","DOI":"10.4103\/aian.AIAN_170_21","article-title":"Coexistence of autoantibodies and other autoimmune diseases with multiple sclerosis and related disorders \u2013 Experience from the Mangalore Demyelinating Disease Registry (MANDDIR)","volume":"24","author":"Malli","year":"2021","journal-title":"Ann. Indian Acad. Neurol."},{"key":"10.1016\/j.msard.2026.107921_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102210","article-title":"Efficacy and safety of rituximab in multiple sclerosis: experience from a developing country","volume":"43","author":"Mathew","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107921_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578066","article-title":"Predictors of hypogammaglobulinemia and serious infections among patients receiving anti-CD20 therapy","volume":"377","author":"Mears","year":"2023","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2026.107921_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106668","article-title":"Efficacy of alternative versus standard dosing strategies of anti-CD20 monoclonal antibodies in multiple sclerosis: a systematic review and meta-analysis","volume":"103","author":"Mohammadi","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107921_bib0025","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000845","article-title":"Tailoring B-cell depletion therapy in MS according to memory B-cell monitoring","volume":"7","author":"Novi","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"9","key":"10.1016\/j.msard.2026.107921_bib0024","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1177\/13524585211028806","article-title":"Fair and equitable treatment for multiple sclerosis in resource-poor regions: the need for off-label therapies and regional treatment guidelines","volume":"27","author":"Pandit","year":"2021","journal-title":"Mult. Scler. J."},{"issue":"20","key":"10.1016\/j.msard.2026.107921_bib0003","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy","volume":"87","author":"Salzer","year":"2016","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2026.107921_bib0002","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1474-4422(22)00209-5","article-title":"Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomized controlled trial","volume":"21","author":"Svenningsson","year":"2022","journal-title":"Lancet Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826009569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826009569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T08:38:07Z","timestamp":1793954287000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826009569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":25,"alternative-id":["S2211034826009569"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107921","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing rituximab dosing in multiple sclerosis: Real-world outcomes with interval extension","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107921","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107921"}}